Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future
| Autor: | Rakesh Sahay, Ambika Gopalakrishnan Unnikrishnan, Sanjay Kalra, Manash P Baruah, O. Adetunji, Shweta Uppal |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
endocrine system
type 2 diabetes mellitus Endocrinology Diabetes and Metabolism efficacy Incretin 030209 endocrinology & metabolism Taspoglutide Review Article 030204 cardiovascular system & hematology Bioinformatics lcsh:Diseases of the endocrine glands. Clinical endocrinology 03 medical and health sciences Lixisenatide chemistry.chemical_compound 0302 clinical medicine Endocrinology medicine lcsh:RC799-869 glucagon-like peptide-1 receptor agonists lcsh:RC648-665 Liraglutide business.industry Semaglutide digestive oral and skin physiology Beyond glycaemic control Albiglutide comparison of glucagon-like peptide-1 receptor agonists chemistry Dulaglutide lcsh:Diseases of the digestive system. Gastroenterology business Exenatide hormones hormone substitutes and hormone antagonists medicine.drug |
| Zdroj: | Indian Journal of Endocrinology and Metabolism, Vol 20, Iss 2, Pp 254-267 (2016) Indian Journal of Endocrinology and Metabolism |
| ISSN: | 2230-9500 2230-8210 |
| Popis: | Glucagon-like peptide-1 (GLP-1)-based therapy improves glycaemic control through multiple mechanisms, with a low risk of hypoglycaemia and the additional benefit of clinically relevant weight loss. Since Starling and Bayliss first proposed the existence of intestinal secretions that stimulate the pancreas, tremendous progress has been made in the area of incretins. As a number of GLP-1 receptor agonists (GLP-1 RAs) continue to become available, physicians will soon face the challenge of selecting the right option customized to their patient's needs. The following discussion, derived from an extensive literature search using the PubMed database, applying the terms incretin, GLP-1, exenatide, liraglutide, albiglutide, dulaglutide, lixisenatide, semaglutide, and taspoglutide, provides a comprehensive review of existing and upcoming molecules in the GLP-1 RA class in terms of their structure, pharmacological profiles, efficacy, safety, and convenience. Search Methodology: A literature search was conducted using the PubMed database, applying the terms incretin, GLP-1, exenatide, liraglutide, albiglutide, dulaglutide, lixisenatide, semaglutide, and taspoglutide. Relevant articles were those that discussed structural, pharmacokinetic and pharmacodynamic differences, classification, long-acting and short-acting GLP-1 RAs, phase 3 trials, and expert opinions. Additional targeted searches were conducted on diabetes treatment guidelines and reviews on safety, as well as the American Diabetes Association/European Society for Study of Diabetes (ADA/EASD) statement on pancreatic safety. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|